OmniAb Inc. Unveils OmniUltra Platform for Discovery of Novel Mini-Proteins and Structured Peptides

Reuters
2025/12/16
OmniAb Inc. Unveils OmniUltra Platform for Discovery of Novel Mini-Proteins and Structured Peptides

OmniAb Inc. has released a presentation highlighting the launch of its new OmniUltra platform. The presentation was delivered at the Antibody Engineering & Therapeutics Conference in San Diego and featured contributions from key company executives and scientists, including CEO Matt Foehr, CFO Kurt Gustafson, and SVP of Exploratory Research Yasmina Abdiche, PhD. The OmniUltra platform is described as a novel in vivo technology for the discovery of mini-proteins and structured peptides, with a focus on identifying ultralong CDRH3 antibodies and expanding epitope coverage. The presentation covered the scientific advancements and potential applications of the platform in antibody and peptide therapeutic discovery. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OmniAb Inc. published the original content used to generate this news brief on December 15, 2025, and is solely responsible for the information contained therein.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10